NCT05296135View on ClinicalTrials.gov

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

February 5, 2020

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

OncoPrism-HNSCC™

OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Trial Locations (1)

94131

Curebase, San Francisco

Sponsors
All Listed Sponsors
lead

Cofactor Genomics, Inc.

INDUSTRY

NCT05296135 - Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer | Biotech Hunter | Biotech Hunter